Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06021080

Enrollment

Registered

2023-09-01

Start date

2023-10-09

Completion date

2026-12-09

Last updated

2025-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Injury, Regional Citrate Anticoagulation, Continuous Renal Replacement Therapy

Keywords

Renal Injury, Regional citrate anticoagulation, Continuous renal replacement therapy

Brief summary

It is unclear whether different modes of continuous renal replacement therapy (CRRT) impact post-filter ionized calcium concentrations during regional citrate anticoagulation (RCA) when using calcium-containing replacement fluid. This prospective, single-center, observational cohort study will screen all patients receiving CRRT for eligibility. General clinical information will be collected before commencing CRRT treatment. Patients will be randomly assigned to either the veno-venous hemofiltration (CVVH) or continuous veno-venous hemodialysis (CVVHD) group and switch to the alternative mode in the subsequent treatment session. Pre-filter and post-filter ionized calcium, systemic total and ionized calcium, and effluent total and ionized calcium will be measured 2 hours after the initiation of CRRT. Electrolyte levels, arterial blood gases, hourly citrate dose, and total citrate dose will be recorded every 6 hours until the end of CRRT. The primary outcome is the difference in ionized calcium concentrations at each site over time between the two modes.

Interventions

PROCEDURECVVH

CVVH therapy

PROCEDURECVVHD

CVVHD therapy

Study design

Observational model

CASE_CROSSOVER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

1. Age ≥ 18 years old; 2. Receiving citrate anticoagulation; 3. Obtain Informed consent from patients or next of kin.

Exclusion criteria

1. Pregnant or lactating women; 2. Allergic to citrate anticoagulants; 3. Severe liver dysfunction (total bilirubin levels exceeding two times the normal range); 4. Hypoxemia (PaO2 \< 60 mmHg); 5. Inadequate tissue perfusion (blood pressure \< 90/60 mmHg despite high doses of vasoactive agents); 6. Hyperlactatemia (lactate\> 4 mmol/L); 7. Hypernatremia; 8. Estimated length of hospital stay \< 48h; 9. Participated in other studies.

Design outcomes

Primary

Measure	Time frame	Description
Post-filter iCa	2 hours after the initiation of CRRT	The post-filter ionized calcium concentration
Serum iCa	2 hours after the initiation of CRRT	Serum ionized calcium concentration
Serum Ca2+	2 hours after the initiation of CRRT	Serum total calcium concentration
Effluent Ca2+	2 hours after the initiation of CRRT	Effluent total calcium concentration

Secondary

Measure	Time frame	Description
Incidence of new-onset metabolic complications	48 hours after the initiation of CRRT	Including hypercalcemia, hypocalcemia, metabolic acidosis, metabolic alkalosis, citrate accumulation, hypernatremia, and hyponatremia

Countries

China

Contacts

Primary ContactHan Chen, Ph.D., M.D.

hanchen.cn@icloud.com+86 591 88217010

Backup ContactWan-Li Yan, M.D.

1727731759@qq.com+86 591 88217011

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026